Duvelisib Granted Priority Review for CLL and Follicular Lymphoma
Jason M. Broderick
The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.
Under the priority designation, the FDA will review the NDA within six months from the acceptance of the filing, compared with the standard 10 months. The FDA is scheduled under the Prescription Drug User Fee Act to make its decision by October 5, 2018.
The NDA is based on data from the phase 3 DUO trial and the phase 2 DYNAMO study. In DUO, duvelisib reduced the risk of disease progression or death by 48 percent versus Arzerra (ofatumumab) in patients with relapsed/refractory CLL/SLL. In the overall population, the median progression-free survival (PFS) with the PI3K-delta and -gamma inhibitor was 3.4 months longer with duvelisib compared to Arzerra. In patients with a 17p deletion (del[17p]), the median PFS benefit was 3.7 months.
In the DYNAMO study, duvelisib demonstrated an overall response rate (ORR) of 46 percent for patients with indolent non-Hodgkin lymphoma (iNHL), including 41 percent in patients with follicular lymphoma.
“Obtaining priority review in the United States for duvelisib marks another important milestone for Verastem and speaks to the unmet need in relapsed/refractory CLL/SLL and FL and the urgency to identify effective therapies to treat these patients,” Robert Forrester, president and CEO of Verastem, the manufacturer of duvelisib, said in a statement.
“As an orally administered therapy, we believe duvelisib will provide an important treatment option for patients with CLL/SLL and follicular lymphoma, and for the physicians who treat them. We look forward to working with the FDA during the review process,” added Forrester.
The phase 3 DUO study randomized 319 patients with CLL/SLL in a 1:1 ratio to duvelisib at 25 mg twice daily until disease progression or unacceptable toxicity, or Arzerra at 300 mg on day one, followed by seven weekly infusions and four monthly infusions of 2000 mg.
The median PFS was 13.3 months in the duvelisib arm compared with 9.9 months in the Arzerra arm. In patients with del(17p), the median PFS was 12.7 versus 9.0 months, respectively.
In the overall population, the ORR with duvelisib was 73.8 percent versus 45.3 percent with Arzerra and lymph-node burden was reduced by more than half in 85 percent versus 16 percent of patients, respectively. Among patients with del(17p), the ORR was 70.0 percent versus 43.0 percent with duvelisib versus ofatumumab, respectively. In the intent-to-treat population, overall survival (OS) between the 2 arms was similar.
The median time on treatment was 50.3 weeks (range, 0.9-160.0) versus 23.1 weeks (range, 0.1-26.1) in the duvelisib and Arzerra arms, respectively. The most common grade ≥3 adverse events (AEs) in the duvelisib group were neutropenia (30 percent) and anemia (13 percent).
The most frequent nonhematologic grade 3 or higher AEs were diarrhea (15 percent), pneumonia (14 percent) and colitis (12 percent). There were four patient deaths associated with duvelisib treatment-related AEs: general physical health deterioration (one patient), pneumonia staphylococcal (two patients), and sepsis (one patient).
The open-label phase 2 DYNAMO study, which began enrolling in May 2013, included patients with iNHL who were refractory to Rituxan (rituximab) and either chemotherapy or radioimmunotherapy. Among the 129 enrolled patients, the disease types included follicular lymphoma (83 patients), SLL (28 patients), and marginal zone lymphoma (18 patients). Continuous duvelisib was administered at 25 mg twice daily.
The ORRs in the follicular lymphoma, SLL, and marginal zone lymphoma groups were 41 percent, 68 percent, and 33 percent, respectively. The median duration of response was 9.9 months. At a median follow-up of 11.5 months, the median OS in the entire iNHL population was 18.4 months and the median PFS was 8.4 months.
The most common grade 3r higher o AEs were neutropenia (23 percent), anemia (12 percent), thrombocytopenia (10 percent), and diarrhea (15 percent). Seventeen percent of patients discontinued duvelisib due to an AE. There were six patient deaths related to AEs.